Literature DB >> 7518349

Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis.

W D Tilley1, S S Lim-Tio, D J Horsfall, J O Aspinall, V R Marshall, J M Skinner.   

Abstract

To determine whether multiple features of immunohistochemical staining of the androgen receptor (AR) in prostate cancer could reliably predict androgen dependence, tumor biopsy specimens from 30 patients (stages A-D2) were stained using anti-peptide antibodies to the amino- and carboxyl-terminal of the AR. Measurements were made of the mean area and total amount (i.e., integrated optical density) of AR staining in at least 20 fields per section using a color video image analysis system, and the mean intensity of AR staining per cell and the percentage of AR positive tumor cells were derived. Video image analysis measurement identified quantitative differences in AR staining between the two antibodies, suggesting that this approach may provide a means of identifying receptor variants in prostate tumors. The AR staining measurements were analyzed by discriminant function analysis to assign individual cases to good and poor clinical outcome groups. AR staining features measured with a single antibody (e.g., amino-terminal) were sufficient to predict outcome following hormonal therapy in stage D2 patients (predictive value, 1.0), whereas all features of AR staining measured with both antibodies were required for the entire patient group (predictive value, 0.97). The principal discriminant in both patient groups contributing to the correct assignment of outcome was the mean intensity of AR staining per cell. These findings suggest that AR staining features measured by video image analysis have the potential to predict outcome in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518349

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.

Authors:  Nathan A Lack; Peter Axerio-Cilies; Peyman Tavassoli; Frank Q Han; Ka Hong Chan; Clementine Feau; Eric LeBlanc; Emma Tomlinson Guns; R Kiplin Guy; Paul S Rennie; Artem Cherkasov
Journal:  J Med Chem       Date:  2011-11-18       Impact factor: 7.446

2.  Androgen receptor expression in primary prostate cancers of Lobund-Wistar rats and in tumor-derived cell lines.

Authors:  J M Bentel; M A Pickering; M Pollard; J A Clements; W D Tilley
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

3.  Corneal graft rejection occurs despite Fas ligand expression and apoptosis of infiltrating cells.

Authors:  K A Williams; S D Standfield; J R Smith; D J Coster
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

Review 4.  Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer.

Authors:  Petros D Grivas; Diane M Robins; Maha Hussain
Journal:  Crit Rev Oncol Hematol       Date:  2012-06-16       Impact factor: 6.312

5.  TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains.

Authors:  Peyman Tavassoli; Latif A Wafa; Helen Cheng; Amina Zoubeidi; Ladan Fazli; Martin Gleave; Robert Snoek; Paul S Rennie
Journal:  Mol Endocrinol       Date:  2010-02-24

6.  Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft.

Authors:  Desok Kim; Christopher W Gregory; Frank S French; Gary J Smith; James L Mohler
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

7.  Negative modulation of androgen receptor transcriptional activity by Daxx.

Authors:  Ding-Yen Lin; Hsin-I Fang; Ai-Hong Ma; Yen-Sung Huang; Yeong-Shiau Pu; Guido Jenster; Hsing-Jien Kung; Hsiu-Ming Shih
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

8.  Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Authors:  Miriam S Butler; Carmela Ricciardelli; Wayne D Tilley; Theresa E Hickey
Journal:  Horm Cancer       Date:  2013-02-27       Impact factor: 3.869

Review 9.  A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Authors:  James L Mohler
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

10.  Prostate cancer in a transgenic mouse.

Authors:  N M Greenberg; F DeMayo; M J Finegold; D Medina; W D Tilley; J O Aspinall; G R Cunha; A A Donjacour; R J Matusik; J M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.